MARKET

DNLI

DNLI

Denali Therapeut
NASDAQ
25.68
-1.53
-5.62%
After Hours: 25.95 +0.27 +1.05% 18:24 07/10 EDT
OPEN
27.06
PREV CLOSE
27.21
HIGH
27.11
LOW
25.25
VOLUME
1.40M
TURNOVER
--
52 WEEK HIGH
27.30
52 WEEK LOW
12.58
MARKET CAP
4.08B
P/E (TTM)
-8.9148
1D
5D
1M
3M
1Y
5Y
1D
Denali wins FDA accelerated approval for Hunter syndrome brain-penetrant enzyme therapy AVLAYAH
PUBT · 2d ago
T. Rowe Price’s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI)
Simply Wall St · 2d ago
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), BioMarin Pharmaceutical (BMRN) and Precision BioSciences (DTIL)
TipRanks · 2d ago
Weekly Report: what happened at DNLI last week (0629-0703)?
Weekly Report · 5d ago
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally
Simply Wall St · 6d ago
Denali’s New Pompe Disease Trial Adds Depth to Its Rare Disease Pipeline
TipRanks · 06/29 16:31
Weekly Report: what happened at DNLI last week (0622-0626)?
Weekly Report · 06/29 09:15
Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale
Simply Wall St · 06/24 02:27
More
About DNLI
Denali Therapeutics Inc. is a biopharmaceutical company establishing a new class of biotherapeutics designed to cross the blood-brain barrier using its TransportVehicle platform. It is focused on building a portfolio of therapeutic candidates by investing in its TV franchises, i.e., Enzyme TV (ETV), Oligonucleotide TV (OTV), and Antibody TV (ATV), to advance programs for rare diseases, such as lysosomal storage diseases, and common diseases, such as Alzheimer's disease and Parkinson's disease. Its most advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (Hunter syndrome). TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A), DNL593 (PTV:PGRN) for frontotemporal dementia-granulin, DNL628 (OTV:MAPT) for Alzheimer’s disease, and DNL952 (ETV:GAA) for Pompe disease. It is also pursuing opportunities in other disease areas including oncology.

Webull offers Denali Therapeutics Inc stock information, including NASDAQ: DNLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DNLI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DNLI stock methods without spending real money on the virtual paper trading platform.